Left ventricular function following thrombolytic therapy for myocardial infarction

Journal of Interventional Cardiology

Volumn 11, Issue 1, 1998, Pages 9-18

  French, John K ^a   Hyde, Thomas A ^a   White, Harvey D ^a  

^a GREEN LANE HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; RETEPLASE; STREPTOKINASE;

ACUTE HEART INFARCTION; DRUG EFFECT; FIBRINOLYTIC THERAPY; HEART LEFT VENTRICLE FUNCTION; HUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0031921261     PISSN: 08964327     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1540-8183.1998.tb00090.x     Document Type: Review

References (67)

1. DeWood MA, Spores J, Notske R, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980;303:897-902.
2. French JK, Williams BF, Hart HH, et al. Prospective evaluation of eligibility for thrombolytic therapy in acute myocardial infarction. Br Med J 1996;312:1637-1641.
3. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994;343:311-322.
4. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-682.
5. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction [published erratum appears in N Engl J Med 1994;330:516]. N Engl J Med 1993;329:1615-1622.
6. The ISAM Study Group. A prospective trial of intravenous streptokinase in acute myocardial infarction (ISAM): Mortality, morbidity, and infarct size at 21 days. N Engl J Med 1986; 314:1465-1471.
7. Bassand JP, Faivre R, Becque O, et al. Effects of early high-dose streptokinase intravenously on left ventricular function in acute myocardial infarction. Am J Cardiol 1987;60:435-439.
8. Durand P, Asseman P, Pruvost P, et al. Effectiveness of intravenous streptokinase on infarct size and left ventricular function in acute myocardial infarction: Prospective and randomized study. Clin Cardiol 1987;10:383-392.
9. White HD, Norris RM, Brown MA, et al. Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction. N Engl J Med 1987;317: 850-855.
10. Kennedy JW, Martin GV, Davis KB, et al. The Western Washington intravenous streptokinase in acute myocardial infarction randomized trial [published erratum appears in Circulation 1988;77:1037]. Circulation 1988;77:345-352.
11. Guerci AD, Gerstenblith G, Brinker JA, et al. A randomized trial of intravenous tissue plasminogen activator for acute myocardial infarction with subsequent randomization to elective coronary angioplasty. N Engl J Med 1987;317:1613-1618.
12. National Heart Foundation of Australia coronary thrombolysis group. Coronary thrombolysis and myocardial salvage by tissue plasminogen activator given up to 4 hours after onset of myocardial infarction. Lancet 1988;I:203-208.
13. O'Rourke M, Baron D, Keogh A, et al. Limitation of myocardial infarction by early infusion of recombinant tissue-type plasminogen activator. Circulation 1988;77:1311-1315.
14. Armstrong PW, Baigrie RS, Daly PA, et al. Tissue plasminogen activator: Toronto (TPAT) placebo-controlled randomized trial in acute myocardial infarction. J Am Coll Cardiol 1989;13:1469-1476.
15. Meinertz T, Kasper W, Schumacher M, et al. The German multicenter trial of anisoylated plasminogen streptokinase activator complex versus heparin for acute myocardial infarction. Am J Cardiol 1988;62:347-351.
16. Bassand JP, Machecourt J, Cassagnes J, et al. Multicenter trial of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction: Effects on inlarct size and left ventricular function. J Am Coll Cardiol 1989;13:988-997.
17. Serruys PW, Simoons ML, Suryapranata H, et al. Preservation of global and regional left ventricular function after early thrombolysis in acute myocardial infarction. J Am Coll Cardiol 1986;7:729-742.
18. Van de Werf F, Arnold AER, for the European Cooperative Study Group for Recombinant Tissue Type Plasminogen Activator. Intravenous tissue plasminogen activator and size of infarct. left ventricular function, and survival in acute myocardial infarction. Br Med J 1988;297:1374-1379.
19. Simoons ML, Serruys PW, van den Brand M, et al. Improved survival after early thrombolysis in acute myocardial infarction: A randomised trial by the Interuniversity Cardiology Institute in the Netherlands. Lancet 1985;II:578-582.
20. Smalling RW, Bode C, Weaver WD, et al. Favorable impact of early patency and a third generation thrombolytic agent on left ventricular function and survival in acute myocardial infarction: A meta analysis of the RAPID I and RAPID II trials. Circulation. In press.
21. Braunwald E, Kloner RA. The stunned myocardium: Prolonged, postischemic ventricular dysfunction. Circulation 1982;66:1146-1149.
22. Ellis SG, Henschke CI, Sandor T, et al. Time course of functional and biochemical recovery of myocardium salvaged by reperfusion. J Am Coll Cardiol 1983;1:1047-1055.
23. Sheehan FH, Doerr R, Schmidt WG. Early recovery of left ventricular function after thrombolytic therapy for acute myocardial infarction: An important determinant of survival. J Am Coll Cardiol 1988;12:289-300.
24. White HD, Norris RM, Brown MA, et al. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 1987;76: 44-51.
25. Migrino RQ, Young JB, Ellis SG, et al. End-systolic volume index at 90 to 180 minutes into reperfusion therapy for acute myocardial infarction is a strong predictor of early and late mortality. Circulation 1997;96:116-121.
26. Pfeffer JM, Pfeffer MA, Braunwald E. Influence of chronic captopril therapy on the infarcted left ventricle of the rat. Circ Res 1985;57:84-95.
27. Pfeffer MA, Pfeffer JM, Steinberg C, et al. Survival after an experimental myocardial infarction: Beneficial effects of long-term therapy with captopril. Circulation 1985;72:406-412.
28. Pfeffer MA, Lamas GA, Vaughan DE, et al. Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. N Engl J Med 1988;319:80-86.
29. Sharpe N, Murphy J, Smith H, et al. Treatment of patients with symptomless left ventricular dysfunction after myocardial infarction. Lancet 1988;I:255-259.
30. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995;345:669-685.
31. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-3: Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343:1115-1122.
32. Chinese Cardiac Study Collaborative Group. Oral captopril versus placebo among 13,634 patients with suspected acute myocardial infarction: Interim report from the Chinese Cardiac Study (CCS-1). Lancet 1995;345:686-687.
33. Swedberg K, Held P, Kjekshus J, et al. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction: Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 1992;327:678-684.
34. French JK, Amos DJ, Cross DB, et al. Captopril within 6 hours of streptokinase in patients with reduced TIMI flow improves ventricular function in the area at risk. (abstract) Circulation 1996;94(Suppl I):I-189.
35. Pfeffer MA, Greaves SC, Arnold JMO, et al. Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction: The Healing and Early Afterload Reducing Therapy Trial. Circulation 1997;95:2643-2651.
36. Sheehan FH. Determinants of improved left ventricular function after thrombolytic therapy in acute myocardial infarction. J Am Coll Cardiol 1987;9:937-944.
37. Smalling RW, Bode C, Kalbfleisch J, et al. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. Circulation 1995;91:2725-2732.
38. Bode C, Smalling RW, Berg G, et al. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. Circulation 1996;94:891-898.
39. Schwarz F, Schuler G, Katus H, et al. Intracoronary thrombolysis in acute myocardial infarction: Duration of ischemia as a major determinant of late results after recanalization. Am J Cardiol 1982;50:933-937.
40. Mathey DG, Sheehan FH, Schofer J, et al. Time from onset of symptoms to thrombolytic therapy: A major determinant of myocardial salvage in patients with acute transmural infarction. J Am Coll Cardiol 1985;6:518-525.
41. White HD, Cross DB, Elliott JM, et al. Long-term prognostic importance of patency of the infarct-related coronary artery after thrombolytic therapy for acute myocardial infarction. Circulation 1994;89:61-67.
42. Lenderink T, Simoons ML, van Es GA, et al. Benefit of thrombolytic therapy is sustained throughout five years and is related to TIMI perfusion grade 3 but not grade 2 flow at discharge. The European Cooperative Study Group. Circulation 1995;92:1110-1116.
43. French JK, Amos D, Webber B, et al. TIMI 3 flow at 3 weeks following myocardial infarction determines long-term mortality in patients randomized to streptokinase or placebo. (abstract) J Am Coll Cardiol 1997;29(Suppl A):71A.
44. Kennedy JW, Ritchie JL, Davis KB, et al. The Western Washington Randomized Trial of Intracoronary Streptokinase in Acute Myocardial Infarction: A 12-month follow-up report. N Engl J Med 1985;312:1073-1078.
45. Topol EJ, Califf RM, George BS, et al. Insights derived from the thrombolysis and angioplasty in myocardial infarction (TAMI) trials. J Am Coll Cardiol 1988;12:24A-31A.
46. Muller DW, Topol EJ, George BS, et al. Long term follow-up in the thrombolysis and angioplasty in myocardial infarction (TAMI) trials: Comparison with trials of thrombolysis alone (abstract). Circulation 1989:80 Suppl II:520.
47. Flygenring BP, Althouse RG, Sheehan FH, et al. Does vessel patency at the time of hospital discharge following thrombolytic therapy predict survival? (abstract) J Am Coll Cardiol 1990;15:202A.
48. Hochman JS, Choo H. Limitation of myocardial infarct expansion by reperfusion independent of myocardial salvage. Circulation 1987;75:299-306.
49. Sager PT, Perlmutter RA, Rosenfeld LE, et al. Electrophysiologic effects of thrombolytic therapy in patients with a transmural anterior myocardial infarction complicated by left ventricular aneurysm formation. J Am Coll Cardiol 1988;12: 19-24.
50. White HD. Relation of thrombolysis during acute myocardial infarction to left ventricular function and mortality. Am J Cardiol 1990;66:92-95.
51. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;II: 349-360.
52. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986;I:397-402.
53. Gruppo Italiano per lo Studio della Streptochi-nasi nell'Infarto Miocardico (GISSI). Long-term effects of intravenous thrombolysis in acute myocardial infarction: Final report of the GISSI Study. Lancet 1987;II:871-874.
54. AIMS Trial Study Group. Long-term effects of intravenous anistreplase in acute myocardial infarction: Final report of the AIMS Study. Lancet 1990;335:427-431.
55. Wilcox RG, von der Lippe G, Olsson CG, et al. Effects of alteplase in acute myocardial infarction: 6-month results from the ASSET Study. Lancet 1990;335: 1175-1178.
56. Baigent C, Collins R, for the ISIS collaborative group. ISIS-2: 4-year mortality follow-up of 17,187 patients after fibrinolytic and antiplatelet therapy in suspected acute myocardial infarction. (abstract) Circulation 1993;88: I-291.
57. White HD, French JK, Hamer AW, et al. Frequent reocclusion of patent infarct-related arteries between 4 weeks and 1 year: Effects of antiplatelet therapy. J Am Coll Cardiol 1995;25:218-223.
58. Meijer A, Verheugt FWA, Werter CJPJ, et al. Aspirin versus coumadin in the prevention of reocclusion and recurrent ischemia after successful thrombolysis: A prospective placebo-controlled angiographic study: Results of the APRICOT Study. Circulation 1993;87:1524-1530.
59. French JK, Ellis CJ, Webber BJ, et al. Abnormal coronary flow in infarct arteries 1 year after myocardial infarction is predicted at 4 weeks by corrected TIMI frame count and stenosis severity. Am J Cardiol. In press.
60. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: A randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992;339: 753-770.
61. Topol EJ, Califf RM, Van de Werf F, et al. Perspectives on large-scale cardiovascular clinical trials for the new millenium. Circulation 1997;95:1072-1082.
62. Schreiber TL, Miller DH, Silvasi DA, et al. Randomized double-blind trial of intravenous streptokinase for acute myocardial infarction. Am J Cardiol 1986;58:47-52.
63. O'Rourke M, Keogh A, Kelly R, et al. Improved LV ejection fraction at 21 days following coronary occlusion treated by early intravenous rt-PA infusion (abstract). Aust NZJ Med 1988;18:351.
64. Topol EJ, George BS, Kereiakes DJ, et al. A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction. Circulation 1989;79:281-286.
65. White HD, Rivers JT, Maslowski AH, et al. Effect of intravenous streplokinase as compared with that of tissue plasminogen activator after first myocardial after first myocardial infarction. N Engl J Med 1989;320:817-821.
66. Anderson JL, Becker LC, Sorensen SG, et al. Anistreplase versus alteplase in acute myocardial infarction: Comparative effects on left ventricular function, morbidity and 1-day coronary artery patency. J Am Coll Cardial 1992;20: 753-766.
67. Whitlock RML, Bass NM. Left ventricular volume estimation by single-plane right anterior oblique cine angiocardiography. Proceedings of the Biological Engineering Society 20th Anniversary International Conference: London; 1980.